Mike Mosunic

There are two key takeaways we learned this year attending Meeting on the Mesa Cell & Gene Conference 2024 #CGMesa2024. 1.     The first that stood out from the opening keynote to the general session panel discussions to individual company break-out presentations, is hearing about all the therapeutic advancements in drug development and FDA approvals through successful commercialization for so many patients in need suffering from difficult to diagnose and difficult to treat (often life threatening) diseases.    Sitting in the audience quietly saying “Yeah, that was UBC, we did that work”. UBC has helped over 60% of the cell or gene therapies brought to approval and available in market.  UBC drives the top therapies in on-going support after approval. 2.     The second is that visibility is as important as performance. We all think that the quality of our work should speak for itself. And it does, but it is self-limiting. There are so many more patients and colleagues that can benefit from your work. There are numerous important reasons more people should be aware of you and what they should additionally consider when choosing to work with a partner. Being the quiet, unsung hero has its great moments. There is gratitude and encouragement as we work together to minimize suffering in the world. More people and the patients they serve can benefit if they know who you are. More to come regarding what else is essential to consider when choosing a strategic partner in healthcare. Pictured with Brett Huselton, SVP, Strategy, Partnerships & Innovation at UBC. Reach out to learn more about UBC's Evidence, Safety and Patient Access Services. #UBC #realwordevidence #RWE #RWD #safetyandriskmanagement #patientservices

48

4 Comments

📣 📣 📣 Through this partnership, COTA makes our hematologic oncology data available through Panalgo's Instant Health Data Analytics (IHD) platform. The collaboration will initially focus on COTA's hematologic oncology data, with plans to add solid tumor data in the future. The partnership also includes research collaborations and AI/technology co-development opportunities. At COTA, we are known for having the highest quality and most complete oncology RWD from electronic health records (EHRs) sourced from a 50/50 split of academic and community care settings across the U.S. Our data contain complete and concise longitudinal patient journeys that support regulatory submissions and help to answer research questions involving treatment patterns, real-world outcomes, care comparisons, and more. Read the full announcement ➡ link in comments ⬇ #realworlddata #rwd #realworldevidence #rwe #oncologyresearch #pharma

50

2 Comments

Field Reimbursement Managers (FRMs) bridge critical gaps between healthcare providers, specialty pharmacies, and manufacturers to reduce barriers and ensure patients have timely access to life-saving treatments. Figure 1 highlights the deleterious effects of prior authorizations on patients as reported by physicians, underscoring the urgency in addressing these access challenges. ReimbursementAI is a next-generation, AI-powered solution that supports FRMs in proactively managing complex reimbursement cases and overcoming prior authorization delays. With compliance-verified AI and data-driven insights, ReimbursementAI enables FRMs to make faster, informed decisions and better support healthcare providers. This platform ultimately extends the reach and effectiveness of FRM teams, promoting a future where patient access is streamlined and equitable. 📈 Propel your FRM team forward with ReimbursementAI—innovating patient access management for a healthier tomorrow. Read more: https://hubs.ly/Q02XSmsh0 #ReimbursementAI #FieldReimbursement #PatientAccess #HealthcareInnovation

32

Patients with Type 2 diabetes are facing roadblocks to access and benefit from innovative therapies, as key areas of unmet need prevent patients from receiving optimal care. Avalere Health’s experts analyze the clinical bottlenecks that face people with diabetes, and give six recommendations on how the industry can support patients in our new whitepaper: https://bit.ly/3yoVcOC #WeAreAvalereHealth #GLP1 #Diabetes

2

Regeneron is facing a critical strategic decision: Should they persist with the failed #strategy of cannibalizing Eylea 2mg sales with Eylea HD, or should they focus on protecting their $4.5B market share in Eylea 2mg from the onslaught of biosimilars by deploying aggressive incentive programs? In their recent conference call, Regeneron highlighted “stickiness” as a defense for retaining the Eylea 2mg market share—referring to the combination of brand loyalty and switching costs. However, as Ben Franklin wisely said, “To persuade, appeal to incentives, not reason.” For Regeneron, “stickiness” alone is unlikely to outweigh the power of incentives. So, will Regeneron choose to defend Eylea 2mg with incentives, or will they continue with their current strategy, risking significant market share loss? I’m not optimistic. As Charlie Munger aptly put it, “The inconsistency avoidance bias is a strong driver of human decision-making.” #retina #pharmaceuticals #ophthalmology

51

5 Comments

💊 **Navigating Reimbursement Hurdles in Biopharma with Innovative Solutions** The biopharma industry stands on the cutting edge of medical innovation, but the journey from breakthrough to patient bedside is fraught with challenges, especially in securing reimbursement. 🌐 Here's a closer look at these hurdles and how an advanced evidence generation engine (AEGE) can illuminate the path forward: 🔍 **Hurdle 1: Complex Regulations** Navigating the labyrinth of local, national, and international reimbursement regulations is daunting. The dynamic nature of these policies demands vigilance and adaptability. **🛠 Solution**: AEGE provides up-to-the-minute compliance insights, ensuring strategies are always aligned with current regulations. 📉 **Hurdle 2: Data Scarcity and Quality** Payers require concrete evidence to approve new treatments, yet high-quality, real-world data can be elusive. **🛠 Solution**: AEGE aggregates vast datasets from diverse sources, providing robust, actionable evidence that meets the rigorous demands of payers. ⏳ **Hurdle 3: Long Approval Timelines** The extended timelines for reimbursement decisions can delay patient access and affect the financial viability of treatments. **🛠 Solution**: AEGE accelerates evidence generation processes, enabling quicker, data-driven decision-making that can shorten approval timelines. 💸 **Hurdle 4: Cost Justification** Proving the cost-effectiveness of new therapies is critical but challenging. **🛠 Solution**: AEGE delivers comprehensive economic analyses, demonstrating the value propositions of treatments with clear, compelling evidence. 🤝 **Hurdle 5: Stakeholder Alignment** Aligning the varied perspectives and agendas of stakeholders—payers, providers, patients, and regulatory bodies—requires a nuanced approach. **🛠 Solution**: AEGE facilitates transparent communication and shared understanding among stakeholders through detailed, evidence-based reporting. 🌿 **Hurdle 6: Sustainability of Innovation** Continuous innovation is essential, yet sustaining it in the face of reimbursement challenges can be tough. **🛠 Solution**: AEGE offers ongoing insights into market trends and payer priorities, fostering a cycle of innovation that is both dynamic and sustainable. Embracing an advanced evidence generation engine is not just a technological upgrade—it's a strategic evolution. By addressing these hurdles head-on, we can ensure that groundbreaking therapies reach patients faster and more efficiently, turning potential into practice. 🌟 Let's harness the power of data and innovation to revolutionize market access and reimbursement in biopharma. Together, we can pave the way for a healthier tomorrow. 🌍💡 #Biopharma #MarketAccess #Innovation #Healthcare #Reimbursement #AdvancedEvidenceGeneration #PatientAccess

3

🌟 GLP-1’s: Goldcards, Denials, and Prior Auths - Will it Work? With GLP-1 prescribing at an all-time high, how can you manage your budget while maintaining positive member experiences? Join us for a free panel discussion as clinical experts from 9amHealth, Solera Health and SmithRx dive into strategies to balance GLP-1 spend and manage member expectations. Our panel will explore key tactics for thoughtful plan design, mitigating denials' impact on member experience, and ensuring effective outcomes while keeping budgets in line. Speakers: 💫 Avantika Waring, MD, Chief Medical Officer, 9amHealth 💫 Byron Crowe MD, Chief Medical Officer, Solera Health 💫 Alissa Johnson, PharmD, MBA, BCPS, Clinical Strategy Director, SmithRx 🗓️ Tuesday, Sep. 24 🕑 2:00 pm ET 💻 Register now: https://lnkd.in/giq-M3hw #HLTHUSA #GoLiveWebinar #GLP1 #HealthTech #HealthcareInnovation

22

1 Comment

The recent removal of the 100% #AMPcap resulted in some interesting market dynamics. But what is AMP Cap, and why is it important to #plansponsors and manufacturers? When we chatted with Jessin Joseph, PharmD (Senior Director, PBA Services) he explained the history behind AMP Cap, new developments in the wake of the #InflationReductionAct, and how the market has reacted to those changes (among many other topics, like #M3P). Listen to the full episode here: https://okt.to/qdMTmU

3

503A vs. 503B Facilities: Key Differences Explained In pharmaceutical compounding, 503A and 503B facilities stand out for their distinct roles in delivering customized medications. This blog will explore their unique features, how they compare to traditional pharmacies, and the essential dos and don’ts for each. https://lnkd.in/eMEUeY9T

4

An early phase CNS study achieved a 215% increase in average screening rate through targeted interventions on Teckro: https://hubs.li/Q02LxCsp0 Over double the amount of study engagements are tracked from sites with screening activity versus those without. Our seamless digital experience drives market-leading site engagement, captured as actionable data for study teams. With 360° oversight of site behavior and performance, sponsors on Teckro unlock a data-driven approach to improved study outcomes. #teckro #sites #engagement #oncology #clinicaltrials #clinicaltech #siteperformance

13

Why do you think pharmaceutical companies work SO HARD to bring new drugs to the market??? When their patents run out on big drugs like this... And payors say no to the ridiculous costs... The money stops flowing as freely and lower cost generics hit the market This is nothing new but it's important to understand how the market works Good thing AbbVie has Skyrizi, Rinvoq, and Botox (along with a pipeline of other new drugs) to keep its investors happy :) The big question... Will the healthcare system and doctors put their foot in the ground and quit prescribing high-cost drugs that provide marginal gain over generics and other therapies? For as much as healthcare complains about high-cost drugs...they prescribe and push an awful lot of them...hmmm.... #healthcare #business #hr #benefits #insurance #pharma #pbm

10

8 Comments

I spy with my little eye something that starts with GLP and ends with 1 accounting for 4 out of the top 10 drugs by cost in 2023. The time is now for a rock solid strategy around GLP-1 medications including or maybe even more importantly: How to support patients coming off the drugs... #dooableHealth #makorx #oneful #rxstrategy #glp-1

5

Do you have questions about GLP-1s, their impact, and how to engage and activate consumers looking for solutions? Join me and Alyssa Billingsley, PharmD on Weds Nov 6th at 2pm ET as we discuss Navigating the GLP-1 Landscape with CHPA.

36

Prescriber testimonials for infusion centers can help build a strong reputation and be incredibly influential. These testimonials not only help demonstrate the quality of your services but also serve as a trust-building tool for potential new referrals. However, getting busy prescribers to share their experiences requires a strategic approach—especially when their time is limited. One of the most effective ways to capture meaningful feedback is by asking the right questions. Instead of overwhelming prescribers with a lengthy list, focus on a few targeted questions that highlight the strengths of your infusion center.  We recommend selecting your favorite three questions to ensure you get quality responses without taking up too much of their time. Questions About Patient Care What makes you confident in referring your patients to our infusion center? How do you feel our team contributes to your patients’ overall treatment journey and outcomes? Can you share an example of how our infusion center has made a positive impact on one of your patients? What do you believe sets our infusion center apart in terms of patient comfort and care? What aspects of our patient care approach stand out to you as particularly beneficial? If you were to recommend our infusion center to a colleague, what would you say? Questions About Communication and Coordination How would you rate the ease of communication and coordination with our team during the referral process? How responsive do you find our staff when it comes to addressing questions or concerns about your patients? In what ways have we supported you in managing your patients’ treatment plans effectively? How does our referral process compare to other infusion centers you’ve worked with? What specific aspects of our service make the referral process smoother for you and your team? Questions About Specific Services at Your Infusion Center Are there any specific treatments or services we offer that you find particularly valuable for your patients? How do you find our support with insurance navigation and financial assistance for your patients? Tips for Reaching Out to Prescribers Given that prescribers are often pressed for time, we recommend selecting just three of these questions when asking for feedback. This makes it easier for them to respond and increases the likelihood of receiving a thoughtful testimonial. You can reach out via email, text, phone, in-person, or even a short survey form—whatever is most convenient for them. Final Thoughts Collecting testimonials from referring prescribers is a valuable part of marketing your infusion center. Their professional endorsement can be a powerful way to showcase your commitment to patient care and build trust with new patients and referring physicians alike. By asking the right questions and keeping the process simple, you can gather compelling testimonials that highlight the unique strengths of your infusion center. #infusioncentermarketing

2

The Medicaid Drug Rebate Program (MDRP) Final Rule introduces significant updates that manufacturers must navigate to remain compliant. To help you address these changes effectively, Riparian, part of Two Labs (an Envision Pharma Group), has developed the Medicaid Final Rule Reference Guide. This guide provides: ✅ Key insights into the Final Rule’s provisions. ✅ Actionable recommendations for compliance and risk management. ✅ Practical tools for evaluating operational and financial impacts. Download your copy now to stay informed and ahead of the curve: https://lnkd.in/gSeC5nDf Riparian combines regulatory expertise and innovative solutions to support your compliance needs. Let us help you meet these new challenges with confidence. #MedicaidFinalRule #GovernmentPricing #PharmaCompliance

15

Avance Clinical is a CRO that offers a tailored suite of services designed to specifically support biotechs. Book a partnering meeting with our expert team, Yvonne Lungershausen, Ben Edwards and Liahna Toy, MBA at BIO International, June 3-6, 2024 in San Diego. Here is what sets us apart: ✅ Full-Service Global CRO: With expertise across 120+ indications, we offer comprehensive support tailored to your specific needs. ✅ Early Phase Specialists in Australia: Benefit from a 43.5% government rebate and globally-accepted data. ✅ Later Phase Specialists: From rare diseases to cell & gene therapies, CNS, and oncology. ✅ Established Market Presence: With head offices in North Carolina, USA, and Adelaide, Australia. ✅ GlobalReady Program: Expand the reach of your drug development program. ✅ ClinicReady Program: Our scientific experts act as your surrogate drug development department, ensuring seamless execution from drug candidate discovery to clinical proof-of-concept. Book now: https://lnkd.in/g9adWvNJ #Biotech #ClinicalResearch #DrugDevelopment #AvanceClinical #Innovation #BIOInternationalConvention #SanDiego #California #USA #Australia #CROforBiotechs Biotechnology Innovation Organization

64

1 Comment

Don't let outdated tech delay your next placement. Find out how DataTools from Bullhorn Marketplace partner Kyloe Partners - Your Bullhorn specialists can help your healthcare staffing firm better manage candidate credentials. 💡👇

7